Speaker: Stewart Tepper

0:06:13

Stewart Tepper, AAN 2019 – Latest therapies in the management of headache

0:11:31

Therapeutic landscape for cluster headache

0:02:00

Discontinuation of anti-CGRP antibodies in non-responders

0:09:29

CONQUER: galcanezumab in treatment-resistant migraine

0:32:15

A Guide to Four Neuromodulation Devices for Migraine Treatment - Spotlight on Migraine S2:Ep9

0:02:05

AHS highlights: atogepant and zavegepant for migraine treatment

0:05:55

Increased placebo response over time in migraine preventive trials

0:27:45

Simplifying New Migraine Treatments: Gepants and Ditans - Spotlight on Migraine S2:Ep7

0:07:37

Erenumab in migraine with or without aura: cardiovascular safety

0:04:17

Assessing the efficacy of fremanezumab on interictal migraine related burden

0:19:11

Benefit of migraine prevention with erenumab

0:20:54

CGRP monoclonal antibodies & migraine management during COVID-19 pandemic

0:15:34

Eptinezumab for Migraine Prevention - Spotlight on Migraine S4:Ep6

0:04:12

Stephen Silberstein, AAN 2019 – Advances in the prevention and treatment of migraine

0:07:32

Richard B Lipton, AAN 2018 – Migraine prevention for highly impacted patients

0:23:34

Ignoring the will of Parliament—What happened in a Manitoba virology lab?

0:01:34

Cluster headache: unmet needs in a disabling condition

0:37:20

Cluster Headache Mechanisms with Dr. Mark Burish

0:20:22

What Migraine Patients Need to Know About Neuromodulation

0:15:14

Overview of Acute Treatment in migraine

0:51:52

PBRN 2016 Plenary 1: Joshua Tepper, MD, MPH, MBA

0:01:30

The CEFALY device: an external trigeminal nerve stimulator

0:35:46

Cluster Headache

0:48:06

Sir Mark Moody-Stuart and Responsible Leadership